Eli Lilly to Seek US Approval for Taltz as Treatment for Pediatric Patients With Plaque Psoriasis

Eli Lilly & Co. (LLY) said Saturday that, following positive study results, it plans to seek US regulatory approval for Taltz (ixekizumab), an injectable drug, to be used as treatment for pediatric patients with moderate to severe plaque psoriasis. The company said that results from its study indicate that Taltz may have the potential to clear skin and reduce itch […]